|
Variablesa
|
Overall survival
|
Relapse-free survival
| |
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
MK5-AS1
|
0.476 (0.309–0.734)
|
0.01
|
0.538 (0.358–0.808)
|
0.003
|
|
Age (year)
|
0.777 (0.501–1.203)
|
0.258
|
0.667 (0.439–1.015)
|
0.059
|
|
Gender
|
0.854 (0.561–1.301)
|
0.463
|
0.885 (0.581–1.348)
|
0.57
|
|
Tumor invasion depth
|
0.463 (0.312–0.688)
|
< 0.001
|
0.48 (0.323–0.713)
|
< 0.001
|
|
Lymph node metastasis
|
0.319 (0.19–0.536)
|
< 0.001
|
0.355 (0.211–0.598)
|
< 0.001
|
|
Distant metastasis
|
0.112 (0.033–0.383)
|
< 0.001
|
0.228 (0.075–0.694)
|
0.009
|
|
TNM stage
|
0.412 (0.27–0.63)
|
< 0.001
|
0.426 (0.279–0.653)
|
< 0.001
|
- aMK5-AS1: low vs high; age: ≤60 vs > 60; gender: male vs female; Tumor invasion depth: T1–T2 vs T3–T4; Lymph node metastasis: N0 vs N1, N2, N3; TNM stage was ranked as I–II vs III–IV
